Diabetes Detection and Prevention in Dermatology
Keywords:
diabetes prevention, diabetes in dermatology, diabetes skin findings, psoriasis and diabetes, diabetes screeningAbstract
We are currently in the midst of an international epidemic of diabetes mellitus (DM) and prediabetes. The prevalence of DM in the United States is estimated at 9.4% of the population across all ages, while an estimated 1 in 3 Americans (33.9%) has prediabetes. According to the WHO, about 60 million people suffer from diabetes in the European Region. Dermatologists may play an important role in tackling this epidemic via efforts to improve early detection of both diabetes and prediabetes. Dermatologists often treat patients with, or at risk of, diabetes. This includes patients who present with cutaneous manifestations such as acanthosis nigricans, as well as patient populations at increased risk, including those with psoriasis, hidradenitis suppurativa, and polycystic ovarian syndrome. Simple screening guidelines can be used to identify patients at risk, and screening can be performed via a single non-fasting blood test. The diagnosis of prediabetes is a key feature in diabetes prevention, as interventions in this group can markedly reduce progression towards diabetes. In addition to referral to a primary care physician, dermatologists may refer these patients directly to structured behavioral lifestyle intervention programs known as diabetes prevention programs. A significant portion of the population lacks routine care by a primary care physician, and current data indicates need for improvement in diabetes screening and prevention among patient groups such as those with psoriasis. These factors highlight the importance of the dermatologist’s role in the detection and prevention of diabetes.
References
National Diabetes Statistics Report, 2017. :20.
Data and statistics. Accessed February 21, 2021. https://www.euro.who.int/en/health-topics/noncommunicable-diseases/diabetes/data-and-statistics
Duff M, Demidova O, Blackburn S, Shubrook J. Cutaneous Manifestations of Diabetes Mellitus. Clin Diabetes. 2015;33(1):40-48. DOI:10.2337/diaclin.33.1.40.
Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84-91. DOI:10.1001/2013.jamadermatol.406.
Garg A, Birabaharan M, Strunk A. Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States. Journal of the American Academy of Dermatology. 2018;79(1):71-76. DOI:10.1016/j.jaad.2018.01.014.
Gambineri A, Patton L, Altieri P, et al. Polycystic Ovary Syndrome Is a Risk Factor for Type 2 Diabetes. Diabetes. 2012;61(9):2369-2374. DOI:10.2337/db11-1360.
Getting Tested | Basics | Diabetes | CDC. Published June 11, 2019. Accessed September 17, 2019. https://www.cdc.gov/diabetes/basics/getting-tested.html
Lifestyle Change Program Details | National Diabetes Prevention Program | Diabetes | CDC. Published August 23, 2019. Accessed September 17, 2019. https://www.cdc.gov/diabetes/prevention/lifestyle-program/lcp-details.html
Levine DM, Linder JA, Landon BE. Characteristics of Americans With Primary Care and Changes Over Time, 2002-2015. JAMA Intern Med. 2020;180(3):463. DOI:10.1001/jamainternmed.2019.6282.
Sattar Naveed, Rawshani Araz, Franzén Stefan, et al. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks. Circulation. 2019;139(19):2228-2237. DOI:10.1161/CIRCULATIONAHA.118.037885.
Barbieri JS, Mostaghimi A, Noe MH, Margolis DJ, Gelfand JM. Use of primary care services among patients with chronic skin disease seen by dermatologists. JAAD International. 2021;2:31-36. DOI:10.1016/j.jdin.2020.10.010.
Khalid U, Hansen PR, Gislason GH, et al. Psoriasis and new-onset diabetes: a Danish nationwide cohort study. Diabetes Care. 2013;36(8):2402-2407. DOI:10.2337/dc12-2330.
Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol. 2017;76(3):393-403. DOI:10.1016/j.jaad.2016.07.065.
Parsi KK, Brezinski EA, Lin T-C, Li C-S, Armstrong AW. Are patients with psoriasis being screened for cardiovascular risk factors? A study of screening practices and awareness among primary care physicians and cardiologists. J Am Acad Dermatol. 2012;67(3):357-362. DOI:10.1016/j.jaad.2011.09.006.
Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239-2251. DOI:10.1016/S0140-6736(17)30058-2.
Lim HW, Collins SAB, Resneck JS, et al. The burden of skin disease in the United States. Journal of the American Academy of Dermatology. 2017;76(5):958-972.e2. DOI:10.1016/j.jaad.2016.12.043.
Shahzad M, Al Robaee A, Al Shobaili HA, Alzolibani AA, Al Marshood AA, Al Moteri B. Skin Manifestations in Diabetic Patients Attending a Diabetic Clinic in the Qassim Region, Saudi Arabia. Med Princ Pract. 2011;20(2):137-141. DOI:10.1159/000321219.
Cruz PD, Hud JA. Excess Insulin Binding to Insulin-Like Growth Factor Receptors: Proposed Mechanism for Acanthosis Nigricans. Journal of Investigative Dermatology. 1992;98(6, Supplement):S82-S85. DOI:10.1111/1523-1747.ep12462293.
Demirseren D, Emre S, Akoglu G, et al. Relationship Between Skin Diseases and Extracutaneous Complications of Diabetes Mellitus: Clinical Analysis of 750 Patients. American Journal of Clinical Dermatology. 2014;15(1):65-70. DOI:10.1007/s40257-013-0048-2.
Morgan AJ, Schwartz RA. Diabetic dermopathy: A subtle sign with grave implications. J Am Acad Dermatol. 2008;58(3):447-451. DOI:10.1016/j.jaad.2007.11.013.
Sibbald C, Reid S, Alavi A. Necrobiosis Lipoidica. Dermatol Clin. 2015;33(3):343-360. DOI:10.1016/j.det.2015.03.003.
O’Toole EA, Kennedy U, Nolan JJ, Young MM, Rogers S, Barnes L. Necrobiosis lipoidica: only a minority of patients have diabetes mellitus. Br J Dermatol. 1999;140(2):283-286. DOI:10.1046/j.1365-2133.1999.02663.x.
Lowitt MH, Dover JS. Necrobiosis lipoidica. J Am Acad Dermatol. 1991;25(5 Pt 1):735-748. DOI:10.1016/s0190-9622(08)80961-9.
de Macedo GMC, Nunes S, Barreto T. Skin disorders in diabetes mellitus: an epidemiology and physiopathology review. Diabetology & Metabolic Syndrome. 2016;8(1):63. DOI:10.1186/s13098-016-0176-y.
Lechner A, Akdeniz M, Tomova-Simitchieva T, et al. Comparing skin characteristics and molecular markers of xerotic foot skin between diabetic and non-diabetic subjects: An exploratory study. J Tissue Viability. 2019;28(4):200-209. DOI:10.1016/j.jtv.2019.09.004.
Kahana M, Grossman E, Feinstein A, Ronnen M, Cohen M, Millet MS. Skin tags: a cutaneous marker for diabetes mellitus. Acta Derm Venereol. 1987;67(2):175-177.
Korman NJ. Management of psoriasis as a systemic disease: What is the evidence? Br J Dermatol. 2019. DOI:10.1111/bjd.18245.
Fleming P, Kraft J, Gulliver WP, Lynde C. The Relationship of Obesity With the Severity of Psoriasis: A Systematic Review. J Cutan Med Surg. 2015;19(5):450-456. DOI:10.1177/1203475415586332.
Phan K, Charlton O, Smith SD. Hidradenitis suppurativa and diabetes mellitus: updated systematic review and adjusted meta-analysis. Clinical and Experimental Dermatology. 2019;44(4):e126-e132. DOI:10.1111/ced.13922.
Ahmad S, Riddle AO, Sayed CJ. Outcomes of Routine Diabetes Screening for Patients with Hidradenitis Suppurativa. J Invest Dermatol. 2020. DOI:10.1016/j.jid.2020.08.016
Gainder S, Sharma B. Update on Management of Polycystic Ovarian Syndrome for Dermatologists. Indian Dermatol Online J. 2019;10(2):97-105. DOI:10.4103/idoj.IDOJ_249_17.
Jacewicz-Święcka M, Kowalska I. Changes in Metabolic Profile in the Women with a History of PCOS—A Long-Term Follow-Up Study. Journal of Clinical Medicine. 2020;9(10):3367. DOI:10.3390/jcm9103367.
Et W, R C-M, Mi C, et al. Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia. Obstet Gynecol. 2011;117(1):6-13. DOI:10.1097/aog.0b013e31820209bb.
Han X, Zhu S, Jemal A. Characteristics of Young Adults Enrolled Through the Affordable Care Act–Dependent Coverage Expansion. Journal of Adolescent Health. 2016;59(6):648-653. DOI:10.1016/j.jadohealth.2016.07.027.
Association AD. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43(Supplement 1):S14-S31. DOI:10.2337/dc20-S002.
Wan MT, Shin DB, Hubbard RA, Noe MH, Mehta NN, Gelfand JM. Psoriasis and the risk of diabetes: A prospective population-based cohort study. J Am Acad Dermatol. 2018;78(2):315-322.e1. DOI:10.1016/j.jaad.2017.10.050.
Bansal N. Prediabetes diagnosis and treatment: A review. World J Diabetes. 2015;6(2):296-303. DOI:10.4239/wjd.v6.i2.296.
Richter B, Hemmingsen B, Metzendorf M, Takwoingi Y. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Cochrane Database Syst Rev. 2018;2018(10). DOI:10.1002/14651858.CD012661.pub2.
Nemah HH, Sebert Kuhlmann AK, Tabak RG. Effectiveness of Program Modification Strategies of The Diabetes Prevention Program: A Systematic Review. Diabetes Educ. 2016;42(2):153-165. DOI:10.1177/0145721716630386.
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677-1686. DOI:10.1016/S0140-6736(09)61457-4.
Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. DOI:10.1056/NEJMoa012512.
Schwarz PEH, Gruhl U, Bornstein SR, Landgraf R, Hall M, Tuomilehto J. The European perspective on diabetes prevention: development and Implementation of A European Guideline and training standards for diabetes prevention (IMAGE). Diab Vasc Dis Res. 2007;4(4):353-357. DOI:10.3132/dvdr.2007.064.
Can you afford to offer a diabetes prevention program? Do this math. American Medical Association. Accessed November 18, 2019. https://www.ama-assn.org/delivering-care/diabetes/can-you-afford-offer-diabetes-prevention-program-do-math
Schwarz PEH, Schuppenies A, Gruhl U, et al. [Prevention of type 2 diabetes in Germany. Ideas, evidence, implementation]. Med Klin (Munich). 2006;101(9):730-736. DOI:10.1007/s00063-006-1100-2.
Ford AR, Siegel M, Bagel J, et al. Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. JAMA Dermatol. 2018;154(8):934-950. DOI:10.1001/jamadermatol.2018.1412.
Debbaneh M, Millsop JW, Bhatia BK, Koo J, Liao W. Diet and Psoriasis: Part I. Impact of Weight Loss Interventions. J Am Acad Dermatol. 2014;71(1):133-140. DOI:10.1016/j.jaad.2014.02.012.
Jensen P, Zachariae C, Christensen R, et al. Effect of Weight Loss on the Severity of Psoriasis: A Randomized Clinical Study. JAMA Dermatol. 2013;149(7):795-801. DOI:10.1001/jamadermatol.2013.722.
Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose–response meta-analysis of prospective studies. Eur J Epidemiol. 2018;33(12):1163-1178. DOI:10.1007/s10654-018-0366-z.
Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr. 2008;88(5):1242-1247. DOI:10.3945/ajcn.2008.26427.
Published
Issue
Section
License
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
